THZ1-R is primarily utilized in the field of biomedical research, particularly in the study of cancer and other diseases related to cell cycle dysregulation. It functions as a potent and selective inhibitor of CDK7, a cyclin-dependent kinase involved in transcription regulation and cell cycle control. By inhibiting CDK7, THZ1-R effectively disrupts the transcription of key oncogenes and halts the proliferation of cancer cells, making it a valuable tool for understanding cancer biology and developing targeted therapies. Researchers also employ THZ1-R to investigate the role of CDK7 in other cellular processes, such as DNA damage response and differentiation, providing insights into potential therapeutic strategies for various diseases. Its specificity and efficacy have made it a promising compound in preclinical studies for cancer treatment.